company background image
CREO logo

Creo Medical Group AIM:CREO Stock Report

Last Price

UK£0.35

Market Cap

UK£121.1m

7D

-5.4%

1Y

39.8%

Updated

27 Mar, 2024

Data

Company Financials +

Creo Medical Group PLC

AIM:CREO Stock Report

Market Cap: UK£121.1m

CREO Stock Overview

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom.

CREO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Creo Medical Group PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Creo Medical Group
Historical stock prices
Current Share PriceUK£0.35
52 Week HighUK£0.50
52 Week LowUK£0.23
Beta0.84
1 Month Change13.01%
3 Month Change-16.77%
1 Year Change39.84%
3 Year Change-83.91%
5 Year Change-82.63%
Change since IPO-56.56%

Recent News & Updates

Market Cool On Creo Medical Group PLC's (LON:CREO) Revenues Pushing Shares 26% Lower

Mar 02
Market Cool On Creo Medical Group PLC's (LON:CREO) Revenues Pushing Shares 26% Lower

Recent updates

Market Cool On Creo Medical Group PLC's (LON:CREO) Revenues Pushing Shares 26% Lower

Mar 02
Market Cool On Creo Medical Group PLC's (LON:CREO) Revenues Pushing Shares 26% Lower

Revenues Tell The Story For Creo Medical Group PLC (LON:CREO) As Its Stock Soars 29%

Dec 29
Revenues Tell The Story For Creo Medical Group PLC (LON:CREO) As Its Stock Soars 29%

Is Creo Medical Group (LON:CREO) Weighed On By Its Debt Load?

Oct 06
Is Creo Medical Group (LON:CREO) Weighed On By Its Debt Load?

Creo Medical (LON:CREO) Is In A Good Position To Deliver On Growth Plans

Feb 03
Creo Medical (LON:CREO) Is In A Good Position To Deliver On Growth Plans

How Many Creo Medical Limited (LON:CREO) Shares Do Institutions Own?

Dec 09
How Many Creo Medical Limited (LON:CREO) Shares Do Institutions Own?

Shareholder Returns

CREOGB Medical EquipmentGB Market
7D-5.4%1.4%2.3%
1Y39.8%3.6%2.7%

Return vs Industry: CREO exceeded the UK Medical Equipment industry which returned 2.3% over the past year.

Return vs Market: CREO exceeded the UK Market which returned 3.7% over the past year.

Price Volatility

Is CREO's price volatile compared to industry and market?
CREO volatility
CREO Average Weekly Movement7.8%
Medical Equipment Industry Average Movement7.6%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.5%

Stable Share Price: CREO's share price has been volatile over the past 3 months.

Volatility Over Time: CREO's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
2003279Craig Gullifordhttps://creomedical.com

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for flexible endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device designed for soft tissue ablation; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues.

Creo Medical Group PLC Fundamentals Summary

How do Creo Medical Group's earnings and revenue compare to its market cap?
CREO fundamental statistics
Market capUK£121.10m
Earnings (TTM)-UK£25.04m
Revenue (TTM)UK£29.27m

4.1x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CREO income statement (TTM)
RevenueUK£29.27m
Cost of RevenueUK£15.15m
Gross ProfitUK£14.12m
Other ExpensesUK£39.16m
Earnings-UK£25.04m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.072
Gross Margin48.25%
Net Profit Margin-85.54%
Debt/Equity Ratio13.3%

How did CREO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.